Iovance Biotherapeutics Inc (GB:0JDK)

Iovance Biotherapeutics Stock Price & Analysis


0JDK Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$5.47 - $20.15
Previous Close$6.73
Average Volume (3M)1.30K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$360.17M
Total Debt (Recent Filing)$80.11M
Price to Earnings (P/E)-2.7
Next EarningsMar 01, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-2.48
Shares Outstanding157,840,581
Standard Deviation0.19
10 Day Avg. Volume80
30 Day Avg. Volume1,298
Price to Book (P/B)2.57
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-3.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside262.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9



What was Iovance Biotherapeutics’s price range in the past 12 months?
Iovance Biotherapeutics lowest stock price was $5.47 and its highest was $20.15 in the past 12 months.
    What is Iovance Biotherapeutics’s market cap?
    Currently, no data Available
    When is Iovance Biotherapeutics’s upcoming earnings report date?
    Iovance Biotherapeutics’s upcoming earnings report date is Mar 01, 2023 which is in 88 days.
      How were Iovance Biotherapeutics’s earnings last quarter?
      Iovance Biotherapeutics released its earnings results on Nov 03, 2022. The company reported -$0.63 earnings per share for the quarter, beating the consensus estimate of -$0.638 by $0.008.
        Is Iovance Biotherapeutics overvalued?
        According to Wall Street analysts Iovance Biotherapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Iovance Biotherapeutics pay dividends?
          Iovance Biotherapeutics does not currently pay dividends.
          What is Iovance Biotherapeutics’s EPS estimate?
          Iovance Biotherapeutics’s EPS estimate is -$0.65.
            How many shares outstanding does Iovance Biotherapeutics have?
            Iovance Biotherapeutics has 157,840,580 shares outstanding.
              What happened to Iovance Biotherapeutics’s price movement after its last earnings report?
              Iovance Biotherapeutics reported an EPS of -$0.63 in its last earnings report, beating expectations of -$0.638. Following the earnings report the stock price went down -3.859%.
                Which hedge fund is a major shareholder of Iovance Biotherapeutics?
                Among the largest hedge funds holding Iovance Biotherapeutics’s share is Perceptive Advisors LLC. It holds Iovance Biotherapeutics’s shares valued at 98M.


                  Iovance Biotherapeutics Stock Smart Score

                  The Iovance Biotherapeutics Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Iovance Biotherapeutics Inc

                  Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Lyell Immunopharma
                  Kura Oncology
                  Replimune Group

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis